Keyphrases
5-fluorouracil (5-FU)
33%
Adaptation
16%
Adjuvant Chemotherapy
22%
Allogeneic
16%
Anaplastic Astrocytoma
16%
Bacterial Colony
16%
Breast
19%
Breast Cancer
66%
Breast Cancer Survivors
24%
Breast Carcinoma
28%
Carboplatin
26%
Chemotherapy
53%
Chemotherapy-induced
16%
Cisplatin
24%
Clinical Oncology
16%
Colonial Expansion
16%
Cyclophosphamide
26%
Dacarbazine
18%
Disease-free Survival
28%
Endometrial Carcinoma
16%
Epirubicin
16%
Fluorescence Polarization
24%
Heavily Pretreated
17%
Interleukin-2
24%
Ipilimumab
24%
Lymph Node-positive Breast Cancer
16%
Lymphocytes
16%
Matrix Test
17%
Melanoma
17%
Melanoma Vaccine
24%
Metastasis
20%
Metastatic Breast Cancer
21%
Metastatic Melanoma
26%
Methotrexate
16%
Mitoxantrone
18%
Nuclear factor-κB
22%
Ovarian Cancer
16%
Overall Survival
35%
Pancreatic Cancer Cells
20%
PCV Chemotherapy
16%
Phase II Study
43%
Phase II Trial
36%
Placebo-controlled
24%
Polarization Change
16%
Postoperative Radiotherapy
16%
Radiotherapy
30%
Strontium-89
16%
Structuredness
30%
Tumor
32%
Vortex
17%
Medicine and Dentistry
Adjuvant Chemotherapy
20%
Adverse Event
12%
Arm
11%
Bone Metastasis
21%
Bone Pain
11%
Breast Cancer
100%
Breast Carcinoma
15%
CA-125
12%
Cancer
12%
Cancer Cell
18%
Cancer Test
16%
Carcinoma
16%
Cisplatin
11%
Clinical Oncology
16%
Colposcopy
16%
Cyclophosphamide
24%
Dacarbazine
16%
Disease Free Survival
23%
Diseases
30%
Endometrium Carcinoma
16%
Fluorescence Polarization
24%
Fluorouracil
25%
Folinic Acid
13%
Gemcitabine
10%
Glioblastoma
16%
Hormone Substitution
16%
Ipilimumab
16%
Kaposi Sarcoma
16%
Krukenberg Tumor
23%
Lomustine
12%
Lymph Node
38%
Lymphocyte
20%
Lymphocyte Activation
12%
Malignant Neoplasm
38%
Melanoma
41%
Melanoma Vaccine
24%
Metastatic Carcinoma
54%
Methotrexate
16%
Mitoxantrone
18%
Neoplasm
46%
Overall Survival
35%
Pancreas Cancer
16%
Placebo
16%
Procarbazine
10%
Programmed Cell Death
15%
Radiation Therapy
50%
Recurrent Disease
27%
Spontaneous Remission
10%
Strontium 89
16%
Vincristine
10%
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
9%
Adverse Event
11%
Anti-Inflammatory Drug
9%
Biological Marker
9%
Bone Metastasis
8%
Breast Cancer
52%
Breast Carcinoma
13%
Budesonide
12%
Carboplatin
26%
Chemotherapy
99%
Cisplatin
29%
Colorectal Carcinoma
20%
Corticotropin
8%
Cyclophosphamide
20%
Cytotoxic T Lymphocyte Antigen 4
9%
Cytotoxicity
10%
Dacarbazine
9%
Diarrhea
10%
Disease Free Survival
20%
Diseases
36%
Endometrium Carcinoma
8%
Epirubicin
16%
Fluoropyrimidine
12%
Fluorouracil
33%
Folinic Acid
16%
Fulvestrant
8%
Gastrointestinal Toxicity
8%
Immunoglobulin Enhancer Binding Protein
9%
Ionizing Radiation
12%
Ipilimumab
24%
Malignant Neoplasm
31%
Melanoma
36%
Metastatic Breast Cancer
20%
Metastatic Melanoma
16%
Methotrexate
16%
Mitoxantrone
18%
Moringa
11%
Moringa oleifera
16%
Neoplasm
33%
Nuclear Factor
17%
Ovary Carcinoma
26%
Overall Survival
27%
Paclitaxel
16%
Pancreas Cancer
24%
Phase II Trials
18%
Placebo
29%
Recurrent Disease
22%
Survival Rate
8%
Tamoxifen
9%
Tolerability
12%
